Previous 10 | Next 10 |
Mateon Therapeutics press release (OTCQB:OTLC): Q1 net loss of $5.09M. For further details see: Mateon Therapeutics reports Q1 results
AGOURA HILLS, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“ Oncotelic ” , “ We ” or the “ Company ”) ( OTCQB: OTLC ) today announced financial results for...
AGOURA HILLS, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) ( OTCQB:OTLC ), developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today anno...
AGOURA HILLS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), is pleased to announce the grant of patent application no. 15/753,882 entitled “USE OF VDAS TO ENHANCE IMMUNOMODULATING...
AGOURA HILLS, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB :OTLC ), today announced the appointment of Dr. Seymour Fein as its Chief Regulatory Officer. Dr. Fein will guide the company...
AGOURA HILLS, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“ Oncotelic ” or the “Company” or “We” ) (OTCQB :OTLC ), today announced the appointment of Dr. Fatih Uckun as its Chief Medical Off...
AGOURA HILLS, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“ Oncotelic ” , “ We ” or the “ Company ”) (OTCQB: OTLC ) today announced financial results for the fu...
Volatility remains the dominant factor across the equities market, with interest rates rising and growth stocks well underwater so far in 2022. Ground zero for this correction is among “long duration assets”, which includes growth stocks with big hypothetical cash flows down the...
AGOURA HILLS, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“ Oncotelic ” or the “Company”) (OTCQB :OTLC ), issued the following shareholder letter today. Dear Fellow Shareholders, We would like to ...
AGOURA HILLS, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) ( OTCQB:OTLC ), today announced the formation of a Joint Venture (“JV”) with Dragon Overseas Capital Limited (ȁ...
News, Short Squeeze, Breakout and More Instantly...
Oncotelic Therapeutics Inc Company Name:
OTLC Stock Symbol:
OTCMKTS Market:
Oncotelic Therapeutics Inc Website:
AGOURA HILLS, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu will speak at the 20th Annual Congress of International Drug Discovery Science & Technology (IDDST) (Europe), June 17-19, 2024 at Budapest, Hungary. ...
AGOURA HILLS, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu will be participating at the BIO International 2024 meeting on June3-6, San Diego. The BIO International Convention is the largest and most comprehensive event ...
AGOURA HILLS, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its Chief Clinical Officer- Dr. Anthony Maida will be participating at the ASCO 2024 meeting. Abstract: e16318. Meta-analysis comparing the incidence of serious adverse events, ov...